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SUMMARY
Introduction Mesenchymal stem cells (MSCs) are a promising tool for regenerative medicine, but due 
to the heterogeneity of their populations, different sources and isolation techniques, the characteristics 
defining MSCs are inconsistent.
Objective The aim of this study was to compare the characteristics of MSCs derived from two different 
human tissues: peripheral blood (PB-MSCs) and umbilical cord Wharton’s Jelly (UC-MSCs).
Methods The PB-MSC and UC-MSC were isolated by adherence to plastic after gradient-density separa-
tion or an explant culture method, respectively, and compared regarding their morphology, clonogenic 
efficiency, proliferating rates, immunophenotype and differentiation potential.
Results MSCs derived from both sources exhibit similar morphology, proliferation capacity and mul-
tilineage (osteogenic, chondrogenic, adipogenic and myogenic) differentiation potential. Differences 
were observed in the clonogenic capacity and the immunophenotype, since UC-MSCs showed higher 
CFU-F (colony-forming units-fibroblastic) cloning efficiency, as well as higher embryonic markers (Na-
nog, Sox2, SSEA4) expression. When additional surface antigens were analyzed by flow cytometry 
(CD44, CD90, CD105, CD33, CD34, CD45, CD11b, CD235a) or immunofluorescent labeling (vimentin, 
STRO-1 and α-smooth muscle actin), most appeared to have similar epitope profiles irrespective of 
MSC source.
Conclusion The results obtained demonstrated that both MSCs represent good alternative sources of 
adult MSCs that could be used in cell therapy applications.
Keywords: mesenchymal stem cells; peripheral blood; umbilical cord; characterization
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INTRODUCTION
Adult mesenchymal stem cells (MSCs), also 
known as mesenchymal stromal cells, are un-
differentiated multipotent cells with the ability 
both to self-renew [1, 2] and to differentiate into 
various cell phenotypes, either of mesenchymal 
origin (osteoblasts, chondrocytes, adipocytes, 
stromal cells, fibroblasts and tendons) [3, 4], or 
non-mesodermal origin (hepatocytes, neural 
cells and epithelial cells) [5]. MSCs reside 
primarily in the bone marrow, but were also 
shown to be present, with similar but not iden-
tical features, in diverse host tissues including 
cord blood and umbilical cord, adult periph-
eral blood, adipose tissue, trabecular bone and 
dental pulp [6-11]. In the human body, MSCs 
are regarded as readily available reservoirs of 
reparative cells able to mobilize, proliferate, 
and differentiate to the appropriate cell type in 
response to specific signals [3, 4]. Due to their 
indispensable regenerative, reparative, ang-
iogenic and immunosuppressive properties, all 
of which collectively point out their therapeu-
tic potential, MSCs have generated increasing 
interest in a variety of biomedical disciplines 
and several areas of ongoing clinical applica-
tions. However, because of the heterogeneity 
of the stem cell populations, as well as differ-
ent sources of their origin and different isola-
tion techniques used among laboratories, the 
characteristics defining MSCs are inconsistent. 
Whether these cell populations isolated from 
diverse sources represent intrinsically similar or 
different cell types is still largely under debate.
OBJECTIVE
The objective of this study was to compare bio-
logical characteristics of MSCs derived from 
two different human tissues with a common 
feature that both are discarded after routine 
medical interventions and therefore are readily 
available source for MSCs isolation. We chose 
to compare MSCs derived from one adult 
tissue, such as peripheral blood, and one peri-
natal tissue, umbilical cord Wharton’s Jelly. 
The comparison was made to describe MSCs 
behavior in cell culture, which could be useful 
for their future use in potential medical pro-
cedures. After isolation and establishment of 
long-term cultures, cells were further charac-
terized regarding their morphology, clonogenic 
efficiency, proliferating rates, immunopheno-
type and differentiation potential.     
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MATERIAL AND METHODS
MSCs isolation
All samples were obtained in accordance with the local 
ethical committee standards and the Declaration of Helsinki 
and after the study subjects provided informed consent.
The peripheral blood-derived MSCs (PB-MSCs) were 
obtained from mononuclear cells of 6 healthy donors 
by density gradient centrifugation, plated at a density of 
4×105/cm2 in 25cm2 flasks in growth medium (GM) con-
taining 10% fetal bovine serum (FBS) and 100 units/ml 
Penicillin/Streptomycin (Pen/Strep) (all from PAA Labo-
ratories, Linz, Austria) in high glucose Dulbecco’s Modi-
fied Eagle’s Medium (DMEM, Sigma-Aldrich, St Luis, MO, 
USA) and cultured in a humidified atmosphere at 37°C 
with 5% CO2. The medium was replaced twice a week and 
non adherent cells were discarded. After two weeks one 
colony of adherent fibroblast-like cells was noticed in one 
of the seeded specimens. When the colony reached the ap-
proximate size of 5 cm2, cells were detached and seeded in 
a new flask in GM. Cells reached confluence after 10 days. 
Following first confluence, cells were passaged regularly.
Umbilical cord-derived MSCs (UC-MSCs) were iso-
lated from umbilical cords obtained after normal full-
term delivery. Six umbilical cords, app. length 20 cm, were 
stored aseptically in cold PBS with 100 µg/ml Pen/Strep, 
and 2.5 µg/ml Amphotericin B (PAA Laboratories), within 
6-24 hours from partum. The umbilical vein and arteries 
were dissected from the tissue, which was then cut into 
fragments (2-3 mm3). Several pieces of tissue were placed 
in a Petri dish with a low amount of GM to allow attach-
ment to the plastic and later on were covered completely 
with culture medium. GM was changed every second 
day. After 7 days, when the cells grew out of the explanted 
tissue, the cord fragments were removed and attached cells 
were cultured until reaching confluence. MSCs were suc-
cessfully isolated from two out of six specimens.
Cell culturing and passaging
After reaching confluence, cells were subcultured routinely 
in GM, using Trypsin/EDTA solution (PAA Laboratories). 
The populations of MSCs were expanded for up to 40 pas-
sages for PB-MSCs, and 20 passages for UC-MSCs. For 
long-term storage of cells, deep-freezing medium consist-
ing of 90% FBS with 10% DMSO was used.
Cell growth assays
Cell growth assays were performed as described [12]. Short-
term cell growth assays were performed by seeding MSCs, 
passage (P) 4 to 6, in 6 well plates at 4×104 cells/well, and 
incubating them in GM at standard culture conditions. At 
days 2, 4, and 7, the cells were detached, counted and their 
viability determined by Trypan blue exclusion test (Invit-
rogen, Carlsbad, CA, USA). These assays were repeated at 
least 3 times for each MSC type. To determine the long-term 
population doubling times MSCs were plated in duplicate in 
6 well plates at 1×104 and 2×105 cells/well. At confluence, the 
cells were detached, counted and reseeded at the initial cell 
density. This procedure was repeated at every passage for 24 
days. The population doubling times (PDT) were calculated 
according to the formula PDT = (T–T0) lg2/(lgNt–lgN0), 
where T0 and T are starting and ending time of cell culture, 
respectively, while N0 and Nt represent the cell number at 
the start and the end of each culture.
Colony-Forming Units-Fibroblastic (CFU-F) assay
CFU-F assays were performed by plating MSCs (P3 to P6) 
in 6 well plates at 10, 50 and 100 cells/well in GM, in two 
replicas. After 14 days under standard culture conditions, 
the cells were fixed with ice-cold methanol and stained 
with 0.3% crystal violet. The number of visible colonies 
(more than 50 cells) was counted.
Flow cytometry analysis
To examine the mesenchymal phenotype, cells (P3 to P6) 
were subjected to flow cytometry analysis. The cells, har-
vested by 1mM EDTA, were washed in cold phosphate-
buffered saline (PBS) with 0.5% bovine serum albumin 
(BSA) from Sigma-Aldrich, and aliquots of 2×105 cells 
were labeled with following monoclonal mouse anti-hu-
man antibodies: anti-CD34-PE (Dako Cytomation, Glos-
trup, Denmark), anti-CD11b-FITC (Biosource, Camarillo, 
CA), anti-CD105-R-PE (Invitrogen), anti-CD45-FITC, 
anti-CD33-Fluorescein, anti-CD235a-PE, anti-CD90-
PE, CD44H-PE (all from R&D Systems, Minneapolis, 
MN, USA). For the embryonic stem cell (ESC) markers 
expression analyses, MSCs were fixed in formaldehyde and 
permeabilized in 90% methanol. Afterwards, aliquots of 
2×105 cells were labeled with primary antibody for SOX2, 
SSEA4 and NANOG and with secondary FITC conju-
gated antibody (all purchased from R&D). To determine 
the level of nonspecific binding, isotype control antibodies 
were used. Flow cytometry was performed using a CyFlow 
CL (Partec, Münster, Germany).
Immunofluorescent labeling
MSCs were seeded over rounded coverslips in GM and 
cultured for 24 hours. After being fixed with 4% formal-
dehyde in PBS, cell monolayers were permeabilized with 
0.1% TritonX-100 (AppliChem, Darmstadt, Germany) 
in PBS and incubated with mouse anti-Vimentin, anti-
STRO-1 and anti-α-SMA (alpha-Smooth Muscle Actin) 
antibody (Sigma-Aldrich), followed by incubation with 
anti-mouse-FITC or anti-mouse-TRITC secondary an-
tibody and 1 µg/ml DAPI (all from Sigma-Aldrich). The 
samples were observed and photographed by an epi-fluo-
rescence microscope.  
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RT-PCR
Two micrograms of total RNA isolated from PB-MSCs 
and UC-MSCs were reverse transcribed using Super-
script II (Invitrogen, Carlsbad, CA). PCRs were performed 
using One-step PCR (Invitrogen). The primer sets used 
were as follows: 5’-GTGATGGCGAAGCGAGTGAA-3’ 
and 5’-CCGAGCCCGAACACACAGAA-3’ for eNOS; 
5’-GCAGGAACCCAGACAACCG-3’ and 5’-GAC-
CCAGGTAGACGATGTAG-3’ for uPA; 5’-GGGAC-
TATCCACCTGCAAGA-3’ and 5’-CCTCCTTGGCG-
TAGTAGTCG-3’ for TGF-β; and 5’-ACCACAGTCCAT-
GCCATCAC-3’, 5’-TCCACCACCCTGTTGCTGTA-3’ 
for GAPDH. Amplicons were resolved in 1.5% agarose 
gel stained with ethidium bromide.
Multilineage differentiation
To determine the differentiation potential of MSCs, third 
to fifth passage cells were seeded in 24 well plates at 4000 
cells/cm2 and cultured in GM. After the cells reached sub-
confluence, GM was replaced with specific osteogenic, 
chondrogenic, adipogenic or myogenic medium as previ-
ously described [13]. As control, cultures with GM only 
were used. To further confirm the identity of differentiated 
cells, they were stained for alkaline-phosphatase (ALP) by 
BICP/NBT, proteoglycans by safranin-O, intracytoplas-
matic lipid droplets by Oil Red O or myotubes formation 
by crystal violet as previously reported [13].
Statistical analysis
To evaluate the probability of significant differences 
among the samples Student’s t-test was performed using 
the Origin PC Program with a p<0.05 considered signifi-
cant.
RESULTS
Isolation and culture of different MSCs
Depending on the starting amount and type of tissue used 
to establish the primary cultures, cells that morphologi-
cally resembled MSCs could be seen as early as 7 days 
post-plating for the UC-MSCs up to 15 days post-plating 
for the PB-MSCs, and the confluence could be reached 
within 10-15 days. Although during the initial culture 
period some morphological heterogeneity in the adher-
ent fraction could be seen, as the cultures were passaged, 
morphological homogeneity was gradually achieved, cells 
were fibroblast-like and no spontaneous differentiation 
was noticed (Figure 1). However, to minimize eventual 
differences due to various starting conditions, the com-
parative analyses presented here were mainly focused on 
cells expanded under similar conditions, i.e. passages later 
than three.
Growth characteristics of different MSC 
populations
When the clonogenic capacity of MSCs was analyzed using 
CFU-F assay, results demonstrated the presence of clo-
nogenic cell populations with fibroblast-like morphology 
in both MSCs examined, but with different frequencies, 
ranging from 25% up to 95%. Common feature among 
tested cells was that MSC populations showed decreases 
in CFU-F frequencies as the initial plating density was 
increased, with the lower cell plating density having the 
highest CFU-F numbers (Graph 1). However, when the 
colony-forming efficiency, defined as the ratio of the 
number of colonies to the number of cells seeded, was 
compared, UC-MSCs had up to 2-fold higher CFU-F ca-
pacity than the PB-MSCs.
Figure 1. Morphology of PB-MSCs and UC-MSCs cultures. Phase contrast micrographs of PB-MSCs (A) and UC-MSCs (B) monolayer cultures at 
passage 4. In monolayer culture, the cells assumed a polymorphic, fibroblast-like morphology, which was maintained throughout the passaging 
process.     
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Culture kinetics of different MSCs are shown in Graph 
2. When the growth kinetics of MSCs was compared by 
seeding 4th to 6th cell passage, the differences related to the 
tissue of origin could not be observed. As shown in Graph 
2A, short-term proliferation assay demonstrated similar 
and extremely high proliferation rate of both PB-MSCs 
and UC-MSCs, as the cell number of these MSC popula-
tions increased almost 40-fold at day 7 after plating.
To confirm expandability of the cells, we evaluated the 
long-term proliferation ability, in which the cells were re-
peatedly seeded at different plating densities to minimize 
any effect of density-dependent cell growth. The PDT 
values obtained for both MSC populations were consistent 
with the results obtained within the initial expandability 
studies, since PB-MSCs and UC-MSCs had short PDTs 
of app. 27 h and 35 h for 5×104 cells plated, respectively 
(Graph 2B).
Immunophenotyping of different MSC populations
The specific markers for MSCs identification were ana-
lyzed by flow cytometry. As expected, both MSCs types 
were negative for hematopoietic markers, such as CD11a, 
CD33, CD45 and Glycophorin-CD235a (Figure 2).   
However, 40% of either PB-MSC or UC-MSC was posi-
tive for CD34. The rate of positivity for the typical mesen-
chymal marker proteins in both PB-MSCs and UC-MSCs 
was low, since both MSCs types were negative for CD90, 
while only 6% of PB-MSC and 10% of UC-MSC ex-
pressed CD105. The presence of another mesenchymal 
marker CD44H was approximately 30% for PB-MSC, and 
ranged 11-22% in UC-MSC cells. Additional immunocy-
tochemical labeling demonstrated that both PB-MSCs and 
UC-MSCs showed positive signal for mesenchymal cell 
marker Vimentin, but were negative for the α-SMA and 
STRO-1 (Figure 3).
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Graph 1. Colony-forming efficiency after expanding MSCs at different 
initial plating densities
MSCs were cultivated at low density (10, 50 or 100 cells/well) in growth medium 
for 14 days and stained for CFU-F with crystal violet. Colony-forming efficiency 
(CFU-F) is defined as the ratio of the number of colonies to the number of cells 
seeded. The results are presented as mean±SD for three experiments, each 
performed in duplicate.
Graph 2. Comparative growth kinetics of PB-MSCs and UC-MSCs 
cultures. (A) Short-term proliferation of MSCs (growth curves of 
representative MSC populations from each source are plotted); 
(B) Population doubling times of representative MSCs in long-
term cultures (the results are expressed as the mean±SD of three 
experiments each performed in duplicate).
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Figure 2. Immunophenotypic profile of PB-MSCs and UC-MSCs. Representative flow cytometry histograms show the expression (unsheded 
peaks) of selected molecules (CD11b, CD33, CD34, CD44H, CD235a, CD105, CD90, CD45) by different MSC populations compared with isotype 
controls (shaded).  
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To further define PB-MSCs and UC-MSCs pheno-
type we analyzed the expression of ESC markers, such as 
Nanog, Sox2 and SSEA4. The results presented in Figure 4, 
evidenced that both MSC types expressed these markers. 
However, UC-MSCs showed higher expression of all 
three analyzed ESC markers, since 50-72% of UC-MSCs 
and 37% of PB-MSCs positively expressed Nanog, while 
40-47% of UC-MSCs and 20% of PB-MSCs positively ex-
pressed Sox2. Percentage of cells expressing SSEA4 was 
21% in PB-MSCs populations, whereas it ranged from 33 
to 83% within UC-MSCs.
The expression of several genes known to be associated 
with MSCs functions, such as endothelial nitric oxide syn-
thase (eNOS), urokinase plasminogen activator (uPA) and 
transforming growth factor beta (TGFb) were analyzed 
by RT-PCR. Obtained results demonstrated that all three 
genes were expressed in both PB-MSC and UC-MSCs, but 
with different expression levels (Figure 5).
Differentiation potential of different MSC  
populations
As a functional assay to confirm MSCs identity, we next 
examined the differentiation potential of MSC popula-
tions from different sources. Although isolation proce-
dures, as well as the immunophenotype profiles of MSCs 
differ, their mesenchymal lineage differentiation capacity 
remained conserved, as MSCs of both populations studied 
exhibited osteogenic (Figure 6A), chondrogenic (Figure 
6B), adipogenic (Figure 6C) and myogenic (Figure 6D) 
differentiation potential.
DISCUSSION
The issue of ready available sources for MSCs isolation 
has growing importance, since these cells can be ben-
eficial agents in regenerative medicine. In this study we 
performed a comparative analysis of MSCs derived from 
peripheral blood and umbilical cords Wharton’s Jelly, nor-
mally discarded as medical waste. The two MSCs types 
showed similar morphology, proliferative rates, differen-
tiation capacity, but differed in clonogenic capacities and, 
in part, in immunophenotype.
Plastic adherence is a well-described property of MSCs 
and one of the three criteria suggested by the International 
Society for Cellular Therapy (ISCT) [14] to define MSCs. 
Although we succeeded to isolate plastic adherent cells, 
from both types of tissue, the amounts of MSCs obtained 
were rather variable. MSCs were obtained from some 
of the umbilical cords, while only one colony of adher-
ent fibroblast-like cells was isolated out of all peripheral 
blood samples. This observation is in agreement with the 
reported data that peripheral blood MSCs are extremely 
low in frequency [15, 16]. Additionally, the elapsed time 
Figure 3. Immunofluorescent labeling of PB-MSCs and UC-MSCs. Representative panels of immunocytochemical detection of mesenchymal 
markers vimentin, STRO-1 and α-SMA on PB-MSCs and UC-MSCs. Positive cytoplasmic staining of MSCs for intracellular MSCs markers by indirect 
immunofluorescence with mouse anti-vimentin, mouse anti-STRO-1 and mouse anti-α-SMA antibody and anti-mouse FITC (green) or TRIC (red) 
secondary antibody, while all nuclei were counterstained with DAPI (blue). Cells were examined using an immunofluorescence microscope.     
183 Srp Arh Celok Lek. 2013 Mar-Apr;141(3-4):178-186
www.srp-arh.rs
Figure 4. Embryonic stem cell markers expression in PB-MSCs and 
UC-MSCs. Representative flow cytometry histograms show the 
expression (unshaded peaks) of selected molecules (SOX2, NANOG 
and SSEA4) by different MSC populations compared to isotype 
controls (shaded).
Figure 5. RT-PCR analysis of eNOS, uPA, TGF-beta mRNA expression in 
PB-MSCs and UC-MSCs. The gel from the representative experiment is 
presented. GAPDH was used as gel loading control.
Figure 6. Differentiation of PB-MSCs and UC-MSCs. (A) Osteogenic differentiation was proved by positive staining for ALP activity; (B) 
Chondrogenic differentiation of MSCs with positive staining of proteoglycans by safranin-O; (C) Adipogenic differentiation was confirmed by 
Oil Red O staining of intracytoplasmatic lipid droplets; (D) Myogenic differentiation characterized by the formation of myotubes stained with 
crystal violet.  
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between the tissue samples removal and processing was 
an important factor for the successful isolation of MSCs, 
particularly for the umbilical cord samples.
The clonogenic capacities of MSCs derived from these 
two sources also differed, as UC-MSCs possessed 2-fold 
higher colony forming efficiency, similar to previous 
reports demonstrating higher proliferation capacities of 
neonatal tissue-derived MSCs in comparison to the adult 
tissue-derived MSCs [15,16, 17]. The greater expansion 
capability of UC-MSCs was confirmed, as the mean dou-
bling time of UC-MSCs was about 30 hours. Although 
the colony forming efficiency of PB-MSC was lower, these 
cells proliferate in the same range as UC-MSCs. The short 
doubling time of PB-MSCs, along with the fact that these 
cells could be expanded up to 40 passages indicated their 
high self-renewal capacity. These characteristics are im-
portant for cell therapy and tissue engineering, since it is 
likely that large amounts of MSCs would be needed for 
potential application.
Next criterion proposed by ISCT to define human 
MSCs is the combination of expressed, mesenchymal, and 
not-expressed hematopoietic cell surface molecules. The 
flow cytometry analysis of MSCs confirmed the absence of 
hematopoietic markers, such as CD11a, CD33, CD45 and 
Glycophorin-CD235a, on both types of MSCs. Consider-
able proportion (40%) of either PB-MSCs or UC-MSCs 
were positive for hematopoietic progenitor cell antigen 
CD34. Similar findings were previously reported for 
MSCs derived from adipose tissue [18, 19]. PB-MSCs 
and UC-MSCs showed low expression of mesenchymal 
markers, as they were negative for CD90, and slightly 
positive for CD105 (6-10%) and CD44H (10-30%). Im-
munocytochemical staining showed that both MSCs were 
positive for Vimentin, while α-SMA and STRO-1 were not 
expressed, which is in agreement with previous findings 
[20]. The expression of Vimentin confirmed mesenchymal 
origin of the cells and distinguished them from epithelial 
and endothelial cells. The disparity observed in the expres-
sion of mesenchymal markers, could be due to various 
reasons. The most important one is the lack of unique 
MSC markers, which along with the recent reports dem-
onstrating that CD105, CD90 and CD44 molecules are 
also expressed on human skin or lung fibroblasts [21, 22], 
point out that additional markers should be used to define 
MSCs. The phenotypic features can be mediated by dif-
ferent tissue sources, the extraction methods employed, as 
well as the in vitro culture conditions that might cause the 
loss of cell surface proteins [17, 23].
Expression of ESC markers, Nanog, Sox2 and SSEA4, 
in PB-MSCs and UC-MSCs, is in agreement with findings 
that human adult MSCs derived from different sources 
may express ESC markers [24, 25]. Although these results 
indicate that both MSCs types are highly multipotent, 
higher percentage of cells positive for ESC markers in 
UC-MSCs population indicated that postnatal UC-MSCs 
are more primitive than adult PB-MSCs. Further support 
that these cells are MSCs are the results showing positive 
expression of eNOS, uPA and TGFb genes, as it has been 
shown that proliferating human BM-MSCs accumulate 
eNOS in the nuclear compartment [26], as well as that 
TGFb is the well known growth factor involved in the cell 
stemness and differentiation [27]. Also, recent studies have 
suggested that MSCs regulatory roles in tissue regenera-
tion involve induction of angiogenesis through uPA pro-
duction [28].
Due to differences in marker expression, the conserved 
mesodermal differentiation capacity within the investi-
gated MSCs seems to be more relevant for their quality at 
present, as the multilineage differentiation potential is the 
hallmark of MSCs. As both MSC populations gave rise to 
four distinct mesenchymal cell lineages, the multipotent 
nature of these MSCs was successfully demonstrated.
A large number of publications on MSCs derived from 
a variety of sources, reported by different groups, dem-
onstrated variability between MSCs. The influence of the 
tissue of origin and the MSC “age” on their biological 
properties cannot be negated. Of particular interest are 
the differences between the MSCs derived from adult 
and neonatal tissues, since MSCs from birth-associated 
tissues are considered more primitive than those ob-
tained from other tissues, with higher proliferative and 
expansion potential, as well as greater accessibility of 
clinical samples [16]. As for PB-MSCs, human MSCs 
that circulate in the bloodstream have been reported, 
but the real tissue origin has been debated, as beside the 
suspected contamination during sample collection and 
the perivascular location of the MSCs, there are specula-
tions that these cells are migrants from the bone marrow 
or other organs [15, 16, 29, 30]. Although it seems that 
the number of circulating MSCs in human blood is low 
under steady-state conditions, the possibility that MSCs 
circulate due to specific organism requirements, e.g. 
during tissue injury, cannot be excluded. The ability 
of hematopoietic stem cells (HSCs) to egress from the 
marrow and home to other sites indicates that MSCs 
might possess this feature, too.
Beside the migratory capabilities, it is possible that 
MSCs can share other characteristics with HSCs, such as 
their hierarchical organization. Namely, HSCs are today 
widely recognized as heterogeneous population with 
hierarchical structure in which the multipotency is pro-
gressively restricted. Therefore, the population diversity 
observed between the MSCs described previously, as well 
as in our study, could be due to the isolation of cells rep-
resenting stem/progenitor cells of different maturity. The 
lack of specific MSC markers makes their identification 
and study more difficult, but until this issue is resolved, 
the ease of accessibility for isolation, high expansion po-
tential in culture, presumptive plasticity, immunosuppres-
sive properties, homing to sites of tissue injury and ethical 
considerations are supporting the use of adult MSCs for 
clinical application.
CONCLUSION
In summary, our findings demonstrate that umbilical cord 
matrix and peripheral blood can be used as alternative        
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sources of adult MSCs. While MSCs therapy is very prom-
ising, the lack of unique phenotypic markers and ineffi-
cient extraction are factors currently limiting their use. 
Further research is necessary to improve our understand-
ing of cells behavior during ex vivo expansion for their safe 
and effective use.
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КРАТАК САДРЖАЈ
Увод Ме  зен  хим  ске ма  тич  не ће  ли  је (ММЋ) су по  себ  но зна  чај-
не за ре  ге  не  ра  тив  ну ме  ди  ци  ну. С об  зи  ром на хе  те  ро  ге  ност 
њи  хо  вих по  пу  ла  ци  ја, ра  зно  вр  сност из  во  ра и тех  ни  ка изо-
ла  ци  је, не по  сто  је је  дин  стве  на обе  леж  ја ко  ја од  ре  ђу  ју ММЋ.
Циљ ра  да Циљ ове сту  ди  је би  ла је упо  ред  на ана  ли  за би-
о  ло  шких ка  рак  те  ри  сти  ка ММЋ изо  ло  ва  них из пе  ри  фер  не 
кр  ви (ПК-ММЋ) и Вар  то  но  ве (Whar ton) слу  зи пуп  ча  не врп  це 
(ВСП-ММЋ).
Ме  то  де ра  да ПК-ММЋ и ВСП-ММЋ су изо  ло  ва  не на осно  ву 
осо  би  не да при  а  ња  ју на пла  стич  ну под  ло  гу, а упо  ре  ђи  ва  не 
су њи  хо  ве мор  фо  ло  шке од  ли  ке, кло  но  ге  ни и про  ли  фе  ра-
тив  ни ка  па  ци  тет, иму  но  фе  но  тип и по  тен  ци  јал ди  фе  рен  ци-
ја  ци  је.
Ре  зул  та  ти До  би  је  ни ре  зул  та  ти по  ка  за  ли су да оба ти  па ММЋ 
има  ју слич  не мор  фо  ло  шке осо  би  не, сли  чан про  ли  фе  ра  тив-
ни ка  па  ци  тет и мул  ти  по  тент  ни по  тен  ци  јал ди  фе  рен  ци  ја  ци  је   
у ће  ли  је раз  ли  чи  тих ме  зен  хим  ских тки  ва (ко  шта  ног, ма-
сног, хр  ска  ви  ча  вог и ми  шић  ног). Раз  ли  ке су при  ме  ће  не 
у кло  но  ге  ном ка  па  ци  те  ту и иму  но  фе  но  ти  пу, бу  ду  ћи да су 
ВСП-ММЋ ис  по  љи  ле ве  ћи ка  па  ци  тет за фор  ми  ра  ње CFU-F 
(енгл. co lony-for ming unit-fi bro blasts), као и ве  ћу екс  пре  си  ју 
мар  ке  ра ти  пич  них за ем  бри  о  нал  не ма  тич  не ће  ли  је (Na nog, 
Sox2, SSEA4). Ис  пи  ти  ва  ње по  вр  шин  ских ан  ти  ге  на ти  пич  них 
за ММЋ (CD44, CD90, CD105, CD33, CD34, CD45, CD11b, CD235a) 
про  точ  ном ци  то  ме  три  јом и иму  но  флу  о  ре  сцент  но обе  ле-
жа  ва  ње до  дат  них ме  зен  хим  ских мар  ке  ра (Vi men tin, STRO-1 
и ал  фа-ак  ти  на глат  ких ми  шић  них ће  ли  ја) ни  је ука  за  ло на 
раз  ли  ке у екс  пре  си  ји ових мар  ке  ра.
За  кљу  чак Оба ти  па ММЋ су по  го  дан ал  тер  на  тив  ни из  вор 
адулт  них ММЋ ко  је би се мо  гле ко  ри  сти  ти у ће  лиј  ској те-
ра  пи  ји.
Кључ  не ре  чи: ме  зен  хим  ске ма  тич  не ће  ли  је; пе  ри  фер  на 
крв; пуп  ча  ник; ка  рак  те  ри  за  ци  ја
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